Barclays raised the firm’s price target on Becton Dickinson (BDX) to $279 from $278 and keeps an Overweight rating on the shares. The firm says ...

Citi analyst Joanne Wuensch maintained a Buy rating on Becton Dickinson (BDX – Research Report) today. The company’s shares closed last Friday ...

Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Merit Medical (MMSI). But which of these two stocks offers value investors a better ...

Shares of Becton Dickinson & Co. BDX slipped 1.60% to $225.85 Wednesday, on what proved to be an all-around rough trading ...

So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Becton Dickinson (NYSE:BDX). Even if this company is fairly valued by ...

Becton, Dickinson and Company is rated a hold due to low growth, valuation concerns, and underperformance compared to healthcare equipment peers. BDX's acquisition of Edwards Lifesciences ...

In trading on Thursday, shares of Becton, Dickinson & Co (Symbol: BDX) crossed below their 200 day moving average of $233.84, changing hands as low as $232.30 per share. Becton, Dickinson & Co ...

Becton Dickinson shares have climbed 8% since the beginning of the year, while the S&P’s 500 index has increased 27%. In the final minutes of trading on Wednesday, shares hit $245.06, a rise of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Becton Dickinson BDX-1.60%decrease; red down pointing triangle and Co. said it plans to break off its bioscience and diagnostic solutions business to focus on medical technology. Chief Executive ...

Becton Dickinson plans to separate its Biosciences and Diagnostic Solutions unit, aiming for completion by fiscal 2026. BD reported Q1 2025 sales of $5.17B, up 9.8% YoY, beating estimates.